Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kaveh Riahi"'
Autor:
Salvatore Siena, H Hirte, Robert L. Coleman, Eric Pujade-Lauraine, Victor Moyo, Francesco Raspagliesi, Philipp Harter, Joseph Pearlberg, Frédéric Selle, Laurence Gladieff, William Kubasek, R. Wendel Naumann, Felix Hilpert, Bambang Adiwijaya, Kaveh Riahi, Gavin MacBeath, David Cibula, Joyce F. Liu, Isabelle Tabah-Fisch, Isabelle Ray-Coquard, Akos Czibere, Andres Poveda, Rachel Nering, Josep M. del Campo, Ignace Vergote
Publikováno v:
Journal of Clinical Oncology. 34:4345-4353
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) –mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This op
Autor:
Debu Tripathy, Javier Cortes, Sara A. Hurvitz, Sunil Verma, Kaveh Riahi, Kathy D. Miller, Joseph G. Reynolds, István Molnár, Thomas Wickham, Ian E. Krop, Denise A. Yardley
Publikováno v:
BMC cancer, vol 16, iss 1
BMC Cancer
BMC Cancer
Background Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36066e07acaf59b1fd040bb8d35892aa
https://escholarship.org/uc/item/7b19m18n
https://escholarship.org/uc/item/7b19m18n
Autor:
Joe Reynolds, Denise A. Yardley, Debu Tripathy, István Molnár, S.A. Hurvitz, S. Verma, Kurt Miller, Kaveh Riahi, Tom Wickham, Ian E. Krop, J. Cortes
Publikováno v:
Cancer Research. 76:OT3-01
Background: Although HER2-targeted therapies such as pertuzumab and T-DM1 have improved patient outcomes, treatment resistance typically occurs. MM-302 is a HER2-targeted liposomal doxorubicin in development by Merrimack Pharmaceuticals. In a Phase 1
Autor:
Kathy Miller, Javier Cortes, Sara A. Hurvitz, Ian E. Krop, Debu Tripathy, Sunil Verma, Kaveh Riahi, Joseph G. Reynolds, Thomas J. Wickham, Istvan Molnar, Denise A. Yardley
Publikováno v:
Journal of Clinical Oncology. 33:TPS641-TPS641
Autor:
Debu Tripathy, Denise A. Yardley, Kaveh Riahi, Kathy D. Miller, Ian E. Krop, Sara A Hurvitz, Sunil Verma, Javier Cortes
Publikováno v:
Cancer Research. 75:OT3-1
Background: Despite improvements in treatment with newly approved HER2-targeted therapies such as pertuzumab and trastuzumab emtansine (T-DM1), HER2-positive metastatic breast cancer (MBC) remains a serious and life-threatening disease. MM-302 is an
Autor:
Liu JF; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Ray-Coquard I; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Selle F; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Poveda AM; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Cibula D; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Hirte H; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Hilpert F; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Raspagliesi F; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Gladieff L; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Harter P; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Siena S; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Del Campo JM; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Tabah-Fisch I; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Pearlberg J; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Moyo V; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Riahi K; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Nering R; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Kubasek W; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Adiwijaya B; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Czibere A; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Naumann RW; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Coleman RL; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Vergote I; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., MacBeath G; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium., Pujade-Lauraine E; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Dec 20; Vol. 34 (36), pp. 4345-4353. Date of Electronic Publication: 2016 Oct 23.